PL3607962T3 - Angiotensyna ii sama lub w połączeniu do leczenia niedociśnienia - Google Patents

Angiotensyna ii sama lub w połączeniu do leczenia niedociśnienia

Info

Publication number
PL3607962T3
PL3607962T3 PL19197866.7T PL19197866T PL3607962T3 PL 3607962 T3 PL3607962 T3 PL 3607962T3 PL 19197866 T PL19197866 T PL 19197866T PL 3607962 T3 PL3607962 T3 PL 3607962T3
Authority
PL
Poland
Prior art keywords
hypotension
angiotensin
alone
treatment
combination
Prior art date
Application number
PL19197866.7T
Other languages
English (en)
Polish (pl)
Inventor
Lakhmir Chawla
Original Assignee
The George Washington University, A Congressionally Chartered Not-For-Profit Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53367119&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3607962(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The George Washington University, A Congressionally Chartered Not-For-Profit Corporation filed Critical The George Washington University, A Congressionally Chartered Not-For-Profit Corporation
Publication of PL3607962T3 publication Critical patent/PL3607962T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/085Angiotensins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL19197866.7T 2013-12-18 2014-12-18 Angiotensyna ii sama lub w połączeniu do leczenia niedociśnienia PL3607962T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361917576P 2013-12-18 2013-12-18
US201461955706P 2014-03-19 2014-03-19

Publications (1)

Publication Number Publication Date
PL3607962T3 true PL3607962T3 (pl) 2026-03-09

Family

ID=53367119

Family Applications (2)

Application Number Title Priority Date Filing Date
PL19197866.7T PL3607962T3 (pl) 2013-12-18 2014-12-18 Angiotensyna ii sama lub w połączeniu do leczenia niedociśnienia
PL14872684T PL2986308T3 (pl) 2013-12-18 2014-12-18 Angiotensyna ii w połączeniu do leczenia niedociśnienia

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL14872684T PL2986308T3 (pl) 2013-12-18 2014-12-18 Angiotensyna ii w połączeniu do leczenia niedociśnienia

Country Status (25)

Country Link
US (7) US9220745B2 (enExample)
EP (2) EP2986308B1 (enExample)
JP (4) JP6824739B2 (enExample)
KR (4) KR20230051721A (enExample)
CN (4) CN111920939A (enExample)
AU (3) AU2014364528C1 (enExample)
BR (1) BR112016013961A2 (enExample)
CA (1) CA2933601A1 (enExample)
CY (1) CY1122604T1 (enExample)
DK (2) DK2986308T3 (enExample)
EA (1) EA037823B1 (enExample)
ES (2) ES3055611T3 (enExample)
FI (1) FI3607962T3 (enExample)
HR (2) HRP20251406T1 (enExample)
HU (1) HUE047062T2 (enExample)
IL (1) IL246162B (enExample)
LT (2) LT2986308T (enExample)
MX (2) MX380968B (enExample)
NZ (1) NZ721089A (enExample)
PL (2) PL3607962T3 (enExample)
PT (2) PT3607962T (enExample)
RS (2) RS59804B1 (enExample)
SI (2) SI2986308T1 (enExample)
SM (2) SMT202000018T1 (enExample)
WO (1) WO2015095535A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9572856B2 (en) 2009-12-16 2017-02-21 The George Washington University a Congressionally Chartered Not-for-Profit Corporation Method of treating low blood pressure
LT2986308T (lt) 2013-12-18 2020-03-25 The George Washington University, A Congressionally Chartered Not-For-Profit Corporation Angiotenzino ii derinys hipotenzijai gydyti
EP3381465A1 (en) * 2014-07-08 2018-10-03 La Jolla Pharmaceutical Company Methods for treating hypotension
WO2016153558A1 (en) 2015-03-20 2016-09-29 Atkinson Arthur J Use of angiotensin ii (aii) receptor agonists to prevent or reduce hemodialysis-associated skeletal muscle cramps
PL3400000T3 (pl) 2016-01-07 2024-04-22 La Jolla Pharma, Llc Sposoby podawania angiotensyny ii
WO2017120440A1 (en) * 2016-01-07 2017-07-13 La Jolla Pharmaceutical Company Methods of administering vasopressors
WO2018191678A1 (en) * 2017-04-14 2018-10-18 La Jolla Pharmaceutical Company Methods for administering angiotensin ii
TW201927331A (zh) * 2017-12-15 2019-07-16 美商拉荷亞製藥公司 血管收縮素組合物及與其相關之方法
US20250366467A1 (en) * 2022-06-15 2025-12-04 Virginia Commonwealth University Methods for fluid resuscitation of an organ donor
JP2025538841A (ja) * 2022-12-12 2025-11-28 プロレタリアート セラピューティクス, インコーポレイテッド 心損傷を処置する方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU181008B (en) 1980-01-18 1983-05-30 Richter Gedeon Vegyeszet Process for producing angiotenzin-ii analogues of antagonistic activity containing sarcosyl-group at the 1-positon,and an alpha-hydroxy-carboxylic acid at the 8-position
US5216025A (en) 1989-09-13 1993-06-01 Board Of Regents, The University Of Texas System Nitric oxide synthesis inhibitors for potentiating the action of pressor agents in certain hypotensive patients
US5444067A (en) 1993-08-30 1995-08-22 Merck & Co., Inc. Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety
CA2448051A1 (en) 2001-06-04 2002-12-12 Human Genome Sciences, Inc. Methods and compositions for modulating ace-2 activity
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
NO20034952D0 (no) 2003-11-06 2003-11-06 Amersham Health As Farmasöytiske forbindelser
JP2007510643A (ja) 2003-11-06 2007-04-26 ジーイー・ヘルスケア・アクスイェ・セルスカプ 医薬化合物
FR2880807B1 (fr) * 2005-01-19 2007-04-13 Aguettant Sa Lab Composition pharmaceutique injectable
EP1942985B1 (en) 2005-09-29 2011-04-27 Fibrogen, Inc. Methods for reducing blood pressure
WO2007076572A1 (en) 2005-12-30 2007-07-12 Howard Florey Institute Of Experimental Physiology And Medicine A method of treatment
EP2029137A2 (en) 2006-06-15 2009-03-04 Gilead Colorado, Inc. Antihypertensive therapy method
WO2008130217A1 (en) * 2006-08-08 2008-10-30 Applied Nanosystems B.V. Cyclic angiotensin analogs
CA2678131A1 (en) 2006-11-17 2008-05-22 Antoine Andremont Colonic delivery using zn/pectin beads with a eudragit coating.
WO2009009907A1 (en) * 2007-07-18 2009-01-22 The University Of British Columbia Use of vasopressin-receptor agonists for the treatment of septic shock
EP2161030A1 (en) * 2008-09-09 2010-03-10 Rijksuniversiteit te Groningen Oxytocin formulations and uses thereof
AU2009319856A1 (en) 2008-11-28 2010-06-03 Abbvie Inc. Stable antibody compositions and methods for stabilizing same
US9572856B2 (en) * 2009-12-16 2017-02-21 The George Washington University a Congressionally Chartered Not-for-Profit Corporation Method of treating low blood pressure
FR2959414B1 (fr) * 2010-04-30 2016-01-08 Luc Quintin Combinaison de molecules aux fins de traitement d'hypotension survenant au cours du choc septique, cardiogenique, ou anaphylactique refractaire, ou hemorragique terminal, apres correction de la volemie et de l'etat de mal asthmatique refractaire
BR112013000744A2 (pt) 2010-07-14 2020-07-14 Cumberland Emerging Technologies, Inc uso de um antagonista de receptor de tromboxana a2 para prevenção ou tratamento de síndrome hepatorrenal,encefalopatia hepática,e doenças associadas
JP6522584B2 (ja) 2013-04-26 2019-05-29 ラ ホヤ ファーマシューティカル カンパニーLa Jolla Pharmaceutical Company 腎不全を処置するための組成物及び方法
LT2986308T (lt) 2013-12-18 2020-03-25 The George Washington University, A Congressionally Chartered Not-For-Profit Corporation Angiotenzino ii derinys hipotenzijai gydyti
US20150286797A1 (en) 2014-04-02 2015-10-08 David R. Ratto System and method for administering medication
EP3381465A1 (en) 2014-07-08 2018-10-03 La Jolla Pharmaceutical Company Methods for treating hypotension
WO2017120440A1 (en) 2016-01-07 2017-07-13 La Jolla Pharmaceutical Company Methods of administering vasopressors
PL3400000T3 (pl) 2016-01-07 2024-04-22 La Jolla Pharma, Llc Sposoby podawania angiotensyny ii
WO2018191678A1 (en) 2017-04-14 2018-10-18 La Jolla Pharmaceutical Company Methods for administering angiotensin ii
TW201927331A (zh) 2017-12-15 2019-07-16 美商拉荷亞製藥公司 血管收縮素組合物及與其相關之方法

Also Published As

Publication number Publication date
EP2986308A4 (en) 2017-01-11
SMT202000018T1 (it) 2020-03-13
KR20220028125A (ko) 2022-03-08
DK2986308T3 (en) 2020-01-27
JP2022137224A (ja) 2022-09-21
EP3607962A1 (en) 2020-02-12
MX380968B (es) 2025-03-12
US9220745B2 (en) 2015-12-29
ES3055611T3 (en) 2026-02-13
CN111920939A (zh) 2020-11-13
NZ721089A (en) 2022-10-28
CN112546197A (zh) 2021-03-26
KR20240154702A (ko) 2024-10-25
FI3607962T3 (fi) 2025-11-24
US11559559B2 (en) 2023-01-24
JP2025114753A (ja) 2025-08-05
US20150164980A1 (en) 2015-06-18
HRP20200009T1 (hr) 2020-03-20
LT3607962T (lt) 2026-01-12
MX2020011190A (es) 2020-11-13
WO2015095535A9 (en) 2016-07-14
EP2986308B1 (en) 2019-10-16
US10493124B2 (en) 2019-12-03
AU2014364528A1 (en) 2016-06-30
SMT202500427T1 (it) 2026-01-12
JP2017501154A (ja) 2017-01-12
WO2015095535A1 (en) 2015-06-25
RS67626B1 (sr) 2026-02-27
EP2986308A1 (en) 2016-02-24
PT3607962T (pt) 2025-11-18
IL246162B (en) 2020-03-31
EA201691258A1 (ru) 2016-11-30
DK3607962T3 (da) 2025-11-17
KR20160117437A (ko) 2016-10-10
US20230226141A1 (en) 2023-07-20
IL246162A0 (en) 2016-07-31
EP3607962B1 (en) 2025-08-13
US20220047669A1 (en) 2022-02-17
PL2986308T3 (pl) 2020-05-18
US20160129072A1 (en) 2016-05-12
AU2020277230A1 (en) 2020-12-24
SI3607962T1 (sl) 2026-02-27
EA037823B1 (ru) 2021-05-25
AU2024219851A1 (en) 2024-10-10
JP7175506B2 (ja) 2022-11-21
CA2933601A1 (en) 2015-06-25
CY1122604T1 (el) 2021-03-12
US10765722B2 (en) 2020-09-08
US20180193407A1 (en) 2018-07-12
MX2016008108A (es) 2017-03-09
PT2986308T (pt) 2020-01-21
AU2014364528C1 (en) 2021-01-07
JP6824739B2 (ja) 2021-02-03
US11096983B2 (en) 2021-08-24
US10028995B2 (en) 2018-07-24
KR20230051721A (ko) 2023-04-18
RS59804B1 (sr) 2020-02-28
HRP20251406T1 (hr) 2026-02-27
AU2014364528A9 (en) 2016-07-28
CN106061493A (zh) 2016-10-26
ES2771749T3 (es) 2020-07-07
LT2986308T (lt) 2020-03-25
JP2019214610A (ja) 2019-12-19
CN119700926A (zh) 2025-03-28
US20190070250A1 (en) 2019-03-07
KR102399383B1 (ko) 2022-05-19
AU2014364528B2 (en) 2020-08-27
US20190328827A1 (en) 2019-10-31
SI2986308T1 (sl) 2020-03-31
BR112016013961A2 (pt) 2017-10-10
HUE047062T2 (hu) 2020-04-28

Similar Documents

Publication Publication Date Title
IL280908B (en) Combination therapy with neoantigen vaccine
PL3542798T3 (pl) Aceklidyna do zastosowania w leczeniu starczowzroczności
PL3607962T3 (pl) Angiotensyna ii sama lub w połączeniu do leczenia niedociśnienia
IL240845A0 (en) Compounds and uses thereof for the modulation of hemoglobin
EP2989214A4 (en) IN SITU INTERACTION DETERMINATION
EP2982331A4 (en) Treatment tool
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
EP3048152A4 (en) POLISHING COMPOSITION
EP2948112A4 (en) TISSUE CHILLING CLAMPS AND CORRESPONDING METHODS
DK3044229T3 (da) Peptider til anvendelse i behandlingen af oral mucositis
ES2664077T8 (es) Cuerpo unido y método de unión
DK3071192T3 (da) Curcuphenolforbindelse til anvendelse i behandling af cancer
PL2988750T5 (pl) Zastosowanie chlorowodorku landilolu w długotrwałym leczeniu tachyarytmii
BR302014001901S1 (pt) Configuração aplicada em organizador
BR302013004618S1 (pt) Configuração aplicada em braçadeira
PL2976089T3 (pl) Zastosowanie sedoheptulozy do zapobiegania lub leczenia zapalenia
EP2958454A4 (en) MAGNETOTHERAPEUTIC BAND
DK2976101T3 (da) Behandlingsfremgangsmåde
IL311363A (en) Compositions for use in treating cognitive impairment
FI20135792A7 (fi) Lattiakaivon insertti ja lattiakaivo
DK3041506T3 (da) Behandlingsfremgangsmåde
GB201311272D0 (en) Anti-microbial agents and uses thereof
ES1078754Y (es) Trampa capturadora de avispas en colmenas
ITFI20130304A1 (it) Bicyclic peptidomimetics for use in the treatment of fungal infections
UA27219S (uk) Форматор-вулканізатор 75" та 88"